Bausch + Lomb Corp
NYSE:BLCO
Intrinsic Value
Bausch + Lomb Corp is a CA-based company operating in Health Care Equipment & Supplies industry. [ Read More ]
The intrinsic value of one BLCO stock under the Base Case scenario is 25.85 USD. Compared to the current market price of 14.5 USD, Bausch + Lomb Corp is Undervalued by 44%.
Valuation Backtest
Bausch + Lomb Corp
Run backtest to discover the historical profit from buying and selling BLCO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bausch + Lomb Corp
Current Assets | 2.7B |
Cash & Short-Term Investments | 331m |
Receivables | 839m |
Other Current Assets | 1.6B |
Non-Current Assets | 10.7B |
PP&E | 1.4B |
Intangibles | 8.2B |
Other Non-Current Assets | 1.1B |
Current Liabilities | 1.6B |
Accounts Payable | 522m |
Accrued Liabilities | 627m |
Other Current Liabilities | 430m |
Non-Current Liabilities | 5B |
Long-Term Debt | 4.5B |
Other Non-Current Liabilities | 481m |
Earnings Waterfall
Bausch + Lomb Corp
Revenue
|
4.1B
USD
|
Cost of Revenue
|
-1.6B
USD
|
Gross Profit
|
2.5B
USD
|
Operating Expenses
|
-2.3B
USD
|
Operating Income
|
213m
USD
|
Other Expenses
|
-473m
USD
|
Net Income
|
-260m
USD
|
Free Cash Flow Analysis
Bausch + Lomb Corp
What is Free Cash Flow?
BLCO Profitability Score
Profitability Due Diligence
Bausch + Lomb Corp's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Bausch + Lomb Corp's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
BLCO Solvency Score
Solvency Due Diligence
Bausch + Lomb Corp's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Bausch + Lomb Corp's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLCO Price Targets Summary
Bausch + Lomb Corp
According to Wall Street analysts, the average 1-year price target for BLCO is 19.81 USD with a low forecast of 16.16 USD and a high forecast of 26.25 USD.
Ownership
BLCO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BLCO Price
Bausch + Lomb Corp
Average Annual Return | -12.67% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -35% |
Market Capitalization | 5.1B USD |
Shares Outstanding | 351 000 000 |
Percentage of Shares Shorted | 3.71% |
BLCO News
Last Important Events
Bausch + Lomb Corp
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Bausch + Lomb Corp
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bausch + Lomb Corp is a CA-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Vaughan, Ontario and currently employs 12,500 full-time employees. The company went IPO on 2022-05-06. Bausch + Lomb Corporation is a Canada-based eye health company. The firm offers lines of contact lenses, intraocular lenses (IOL), medical devices, surgical systems, vitamin and mineral supplements, lens care products, prescription eye-medications and over the counter (OTC) eye health consumer products. The company operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. Vision Care/Consumer Health Care business includes both contact lens and consumer eye care businesses, and includes products, such as Biotrue ONEday daily disposables. Ophthalmic Pharmaceuticals business includes a range of pharmaceutical products for post-operative treatments and treatments for eye conditions, such as glaucoma, eye inflammation, ocular hypertension, and retinal disease. Surgical business includes medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions.
Contact
IPO
Employees
Officers
The intrinsic value of one BLCO stock under the Base Case scenario is 25.85 USD.
Compared to the current market price of 14.5 USD, Bausch + Lomb Corp is Undervalued by 44%.